

Title (en)  
COMPOSITIONS AND METHODS OF ADMINISTERING RAPAMYCIN ANALOGS USING MEDICAL DEVICES FOR LONG-TERM EFFICACY

Title (de)  
ZUSAMMENSETZUNGEN UND VERFAHREN ZUR VERABREICHUNG VON RAPAMYCIN-ANALOGA MIT MEDIZINPRODUKTEN FÜR LANGZEITWIRKUNG

Title (fr)  
COMPOSITIONS ET PROCEDES POUR L'ADMINISTRATION D'ANALOGUES DE RAPAMYCINE AU MOYEN DE DISPOSITIFS MEDICAUX POUR UNE EFFICACITE DE LONGUE DUREE

Publication  
**EP 1877004 A4 20120125 (EN)**

Application  
**EP 06739478 A 20060322**

Priority

- US 2006010700 W 20060322
- US 66448805 P 20050323
- US 71508205 P 20050908
- US 72708005 P 20051014
- US 72687805 P 20051014
- US 72719605 P 20051014
- US 73257705 P 20051017

Abstract (en)  
[origin: WO2007032777A2] Systems and compositions comprising zotarolimus that are safer, more effective and produce less inflammation than rapamycin and paclitaxel systems are disclosed. Medical devices comprising supporting structures capable of containing or supporting a pharmaceutically acceptable carrier or excipient, which carrier or excipient can contain one or more therapeutic agents or substances, with the carrier including a coating on the surface thereof, and the coating having the therapeutic compounds, including, for example, drugs. Supporting structures for the medical devices include coronary stents, peripheral stents, catheters, arterio-venous grafts, by-pass grafts, and drug delivery balloons used in the vasculature. These compositions and systems can be used in combination with other drugs, including anti-proliferative agents, anti-platelet agents, anti-inflammatory agents, anti-thrombotic agents, cytotoxic drugs, agents that inhibit cytokine or chemokine binding, cell differentiation inhibitors, anti-lipaedemic agents, matrix metalloproteinase inhibitors, cytostatic drugs, or combinations of these and other drugs.

IPC 8 full level  
**A61F 2/00** (2006.01); **A61K 31/44** (2006.01); **A61L 31/16** (2006.01)

CPC (source: EP)  
**A61L 31/16** (2013.01); **A61L 2300/416** (2013.01); **A61L 2300/602** (2013.01)

Citation (search report)

- [X] WO 03022807 A2 20030320 - ABBOTT LAB [US], et al
- [X] WO 2004022124 A1 20040318 - ABBOTT LAB [US], et al
- [X] WO 0187372 A1 20011122 - CORDIS CORP [US]
- [X] WO 02062335 A2 20020815 - VASCULAR THERAPIES LLC [US]
- See references of WO 2007032777A2

Citation (examination)  
WO 2005092406 A1 20051006 - ADVANCED CARDIOVASCULAR SYSTEM [US], et al

Designated contracting state (EPC)  
AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU LV MC NL PL PT RO SE SI SK TR

DOCDB simple family (publication)  
**WO 2007032777 A2 20070322; WO 2007032777 A3 20071025**; EP 1877004 A2 20080116; EP 1877004 A4 20120125; EP 3138531 A1 20170308; JP 2008534074 A 20080828; JP 5242374 B2 20130724

DOCDB simple family (application)  
**US 2006010700 W 20060322**; EP 06739478 A 20060322; EP 16171630 A 20060322; JP 2008503210 A 20060322